Fig. 2. Alteration of DNA methylation of the CpG sites of SLC6A12 in tumor metastases from ovarian cancer xenograft mice. The DNA methylation status of the SLC6A12 promoter region was analyzed using the Illumina HumanMethylation450 BeadChip, which contains 18 specific CpG sites at positions 322214–324747 (the human GRCh37/hg19 assembly) within chromosome 12 (upper panel of A). Individual bars represent the mean β-value of methylation at the corresponding CpG site within the SLC6A12 promoter (lower panel of A). Data are shown as the mean±SD. Statistical analyses were performed using Bayesian t-statistics (^**p<0.01, ^***p<0.001) (A). Differences in the DNA methylation status of the 323242 CpG site in SK-OV-3 cells and tumor metastases was analyzed with qMSP. Statistical analyses were performed using one-way ANOVA and Turkey’s multiple comparison post-tests for comparing significance with SK-OV-3 cells (^***p<0.001) (B). DM, differentially methylated CpG site; SLC6A12, solute carrier family 6, member 12; qMSP, quantitative methylation-specific polymerase chain reaction.